The antitumor activity of ND 100 peptide

Chinese Pharmacological Bulletin

Volumn 21, Issue 1, 2005, Pages 114-116

  Zhang, Dong Mei ^a   Chen, Jun Hui ^a   Li, Jun ^a   Wang, Xin Chang ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Antitumor activity; ND 100; Solution phase peptide synthesis

Indexed keywords

ND 100 PEPTIDE; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG SYNTHESIS; ERYTHROCYTE COUNT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LEUKOCYTE COUNT; LEWIS CARCINOMA; LIVER CELL CARCINOMA; MOLECULAR WEIGHT; MOUSE; NONHUMAN; SARCOMA;

EID: 34247506232     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Burzynski SR. Antineoplastons: biochemical defense against cancer[J]. Physiol Chem Phys, 1976,8(3):275-9.
2. Badria F, Mabed M, Khafagy W et al. Potential utility of antineoplaston A-10 levels in breast cancer[J]. Cancer Lett, 2000,155 (1):67-70.
3. Burzynski SR. The present state of antineoplaston research(1) [J]. Integr Cancer Ther, 2004,3(1):47-58.
4. Burzynski SR, Lewy RI, Weaver RA et al. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report[J]. Drugs RD, 2003,4(2):91-101.
5. Chinese source